STOCK TITAN

Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM), a leading biotechnology firm focused on precision genetic medicines, announced that CEO John Evans will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 9:45 a.m. ET in Boston. The event will be accessible via a live webcast on the company's investor website and archived for 60 days. Beam specializes in base editing technology, enabling precise modifications in genetic sequences to develop effective therapeutic strategies for serious diseases. The company is committed to achieving life-long cures through cutting-edge scientific advancements.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022 at 9:45 a.m. ET in Boston.

A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


FAQ

When is Beam Therapeutics' presentation at the Wells Fargo 2022 Healthcare Conference?

Beam Therapeutics will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 9:45 a.m. ET.

Where can I watch the Beam Therapeutics presentation?

The presentation will be available via live webcast on Beam Therapeutics' investor website and archived for 60 days.

What technology does Beam Therapeutics specialize in?

Beam Therapeutics specializes in base editing technology, which enables precise modifications to genetic sequences.

What is Beam Therapeutics' mission?

Beam Therapeutics aims to provide life-long cures to patients suffering from serious diseases through advanced genetic medicines.

Who is presenting for Beam Therapeutics at the conference?

John Evans, the CEO of Beam Therapeutics, will be presenting at the Wells Fargo 2022 Healthcare Conference.

Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Stock Data

2.27B
81.62M
1.42%
93.14%
14.45%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE